Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth Inhibition. (2020)
Attributed to:
Maximising patient benefit: Leeds’ Interdisciplinary approach to translation (CiC 2017)
funded by
UKRI
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1021/acsmedchemlett.0c00186
PubMed Identifier: 32944138
Publication URI: http://europepmc.org/abstract/MED/32944138
Type: Journal Article/Review
Volume: 11
Parent Publication: ACS medicinal chemistry letters
Issue: 9
ISSN: 1948-5875